Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Seminars in Oncology

• Publication date

  2003-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2003.11.018PMID 14727248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.

  2001cited by this paper
• A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.

  2001cited by this paper
• Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.

  2000cited by this paper
• Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

  2000cited by this paper
• Pharmacokinetics of amifostine

  1999cited by this paper
• Pharmacokinetics of amifostine: effects of dose and method of administration.

  1999cited by this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cited by this paper
• Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.

  1985cited by this paper
• The role of WR-2721 in radiotherapy and/or chemotherapy.

  1980cited by this paper
• Biological Characteristics of Some Improved Radioprotectors

  1980cited by this paper
• Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study.

  1976cited by this paper
• Radioprotection of tumor and normal tissues by thiophosphate compounds

  1973cited by this paper
• Cysteine Protection against X Irradiation.

  1949cited by this paper

• MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review

  2023cites this paper
• Oxaliplatin-related neurotoxicity: how and why?

  2006cites this paper
• Chemical radioprotective substances: The past, the present and the future

  2006cites this paper
• Radioprotection in mice following oral delivery of amifostine nanoparticles

  2005cites this paper